ClinicalTrials.gg
CompletedNCT02219880KGADUpdated Oct 15, 2018

Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial

A Phase 4 interventional study of Kava (240mg of kavalactones per day) and Placebo in Generalized Anxiety Disorder, sponsored by University of Melbourne. Completed at 2 sites in Australia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-10-15.

Sponsored by University of Melbourne · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The use of Kava in Generalised Anxiety Disorder: an 18-week double-blind, randomised, placebo-controlled study.

Read the detailed description

The primary aim is to confirm the efficacy and safety of Kava compared to placebo in Generalized Anxiety Disorder (GAD). Secondary aims of the study are to confirm the relationship between specific genetic variations and response to Kava, and to explore the effects of Kava on the expression of specific genes.

Consenting participants will be randomly allocated to take either Kava or placebo over 18 weeks. They will be assessed at regular interviews throughout the trial and will have four blood tests (liver function tests to monitor participant safety, and collection of genetic material providing information on neurochemistry). The design of the study is a multi-centre, 18-week, 2-arm, double-blind randomised clinical trial (RCT) using a standardised pharmaceutical-grade water-soluble extract of Kava (240mg of kavalactones per day) versus placebo in 210 adults with GAD.

02

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • Kava
  • Anxiety
  • Generalized Anxiety Disorder
  • Psychiatric
  • Anxiolytic
  • GABA
  • Kavalactones
03

In context

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

This study's enrollment of 178 is above the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.

Browse Generalized Anxiety Disorder studies →

Lead sponsor

University of Melbourne is the lead sponsor of 87 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

To be considered for inclusion in this study, participants will be required to meet the following criteria:

  • Aged between 18-70 years
  • Meets the Diagnostic and Statistical Manual (DSM) IV and diagnostic criteria for generalised anxiety disorder (GAD) based on structured interview (Mini International Neuropsychiatric Interview-Plus 6 [MINI-Plus 6]. Note that while the MINI-Plus 6 uses the DSM-IV criteria, the same criteria are used in the DSM-V).
  • Presents with anxiety (Hamilton Anxiety Rating Scale ≥ 18) at the time of study entry
  • Fluent in written and spoken English
  • Provides a signed copy of the consent form

Participants are ineligible to enter the trial if they have any of the following conditions:

  • Primary diagnosis other than GAD
  • Presentation of moderate to severe depressive symptoms (Montgomery-Asberg Rating Scale: MADRS ≥ 18 at time of study entry or ≥ 24 at any time during study)
  • Presentation of suicidal ideation (≥ 3 on MADRS suicidal thoughts domain at time of study entry or at any time during study)
  • Current diagnosis of bipolar disorder or schizophrenia on structured interview (MINI Plus)
  • Current substance/alcohol use disorder on structured interview (MINI Plus) Page 21 of 39 Commercial-in-Confidence
  • Currently taking an antidepressant, mood stabiliser, antipsychotic, anticonvulsant, warfarin or thyroxin, or current regular use (more than 2 days per week) of a benzodiazepine or opioid-based analgesic
  • Current use of a psychotropic nutraceutical (e.g. St John's wort)
  • Previous intolerance to kava
  • Three or more failed trials of pharmacotherapy for the current GAD episode
  • Recently commenced psychotherapy (within four weeks of study entry)
  • Known or suspected clinically unstable systemic medical disorder
  • Diagnosed hepato-biliary disease/inflammation
  • Elevated liver enzymes at baseline blood test
  • Pregnancy or breastfeeding, or trying to conceive
  • Not using medically approved (including abstinence) if female and of childbearing age
  • Unable to participate in all scheduled visits, treatment plan, or other trial procedures according to the protocol (except for the optional genetic component)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
178 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Inert tablets matched for colour, size and consistency to active arm treatment. Both treatment arm tablets will match in appearance, and neither participants nor the trial clinicians will know what they are taking.

    Dietary Supplement: Placebo

  • Experimental
    Kava - standardised 240mg kavalactones

    Standardised 240mg kavalactones per day - fixed dose regime of two tablets of kava twice per day

    Dietary Supplement: Kava (240mg of kavalactones per day)

Interventions

  • Dietary supplementPiper methysticum rootStudies of Piper methysticum rootPiper methysticum root pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Kava 60 milligrams per tablet = 240mg of kavalactones per day

    Also known as: Kava, Kavalactones, Piper methysticum

  • Dietary supplementPlacebo

    Inert tablets containing vegetable fibre matched for colour, size and consistency to active arm treatment.

06

What researchers measure

Primary outcomes

  1. Hamilton Anxiety Rating Scale (HAMA) - change in score

    Reduction of participant's anxiety will be assessed on the HAMA from baseline to week 16 across time used a mixed methods model.

    Time frame: 18 weeks

Secondary outcomes

  1. Gamma-aminobutyric acid (GABA) transporter polymorphisms moderating response to study intervention

    Will assess whether response to Kava will be moderated by gamma-aminobutyric acid (GABA) transporter polymorphisms. Specifically, whether rs2601126-T allele or rs2697153-A allele carriers have greater reduction of anxiety

    Time frame: 18 weeks

Other outcomes

  1. Changes in score to psychometric questionnaire measures

    Depressive symptoms on the Montgomery-Asberg Depression Rating Scale (MADRS), self-rated anxiety on the Beck Anxiety Inventory (BAI), pathological worry on the Penn State Worry Questionnaire (PSWQ), and health-related quality of life on the Short Form Survey-12 (SF-12) will also be significantly improved by Kava over placebo; and

    Time frame: 18 weeks

  2. Monoamine and GABA differential gene expression

    Differential gene expression will be assessed from baseline to week 8 from participants in the Melbourne site. This will determine whether Kava increases expression of genes effecting expression of neurochemical e.g. GABA, and monoamines

    Time frame: 8 weeks

07

Study locations

2 sites
  • Royal Brisbane & Women's Hospital
    Brisbane, Queensland 4006, Australia
  • Centre for Human Psychopharmacology - Swinburne University
    Melbourne, Victoria 3122, Australia
08

References and documents

Publications

  • Sarris J, Byrne GJ, Bousman CA, Cribb L, Savage KM, Holmes O, Murphy J, Macdonald P, Short A, Nazareth S, Jennings E, Thomas SR, Ogden E, Chamoli S, Scholey A, Stough C. Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. Aust N Z J Psychiatry. 2020 Mar;54(3):288-297. doi: 10.1177/0004867419891246. Epub 2019 Dec 8. PubMed 31813230 ↗
  • Savage KM, Stough CK, Byrne GJ, Scholey A, Bousman C, Murphy J, Macdonald P, Suo C, Hughes M, Thomas S, Teschke R, Xing C, Sarris J. Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial. Trials. 2015 Nov 2;16:493. doi: 10.1186/s13063-015-0986-5. PubMed 26527536 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in May 2018, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2014
First posted
Aug 19, 2014
StartActual
Oct 13, 2015
Primary completionActual
May 31, 2018
CompletionActual
May 31, 2018
Last update
Oct 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02219880
Lead sponsor
University of Melbourne
Collaborators
Swinburne University of Technology, The University of Queensland
Responsible party
Jerome Sarris (Dr Jerome Sarris, University of Melbourne) — Principal investigator
First posted
Aug 19, 2014
Start date
Oct 13, 2015
Primary completion
May 31, 2018
Completion
May 31, 2018
Last update
Oct 15, 2018

Study contacts

Jerome Sarris, PhD
principal investigator · The University of Melbourne and The Melbourne Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Piper methysticum root

Start the discussion